Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| NNB Nutrition | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Think of this section as your research "elevator pitch." Please briefly describe the question(s) or issues you are addressing with your research (limited to 100 words). You will be able to provide information on specific outcomes, hypothesis, or related analysis in a following question.
Beta-amino isobutyric acid (BAIBA) is a myokine produced in skeletal muscle and has been shown to impact how our body metabolizes fuel. We seek to determine the bioavailability of different doses of orally ingested beta-aminoisobutyric acid (BAIBA).
Once determined eligible and provided consent, participants will be assigned in a randomized, double-blind, placebo-controlled, crossover fashion. Eligible study participants will complete one of five testing conditions outlined below. For each testing condition, study participants will arrive in the lab after observing an overnight fast. Upon arrival, participants will donate the first of seven venous blood samples. Follow-up blood samples will be collected at 30, 60, 90, 120, 240, 300 minutes. The first and last collected samples will be collected into one 8mL SST and three 4mL EDTA tubes, while the second, third, and forth collected samples will be into two 4mL EDTA tubes, and have aliquots of 600 ul of plasma isolated and frozen at -80oC. Collected plasma will be analyzed for changes in beta-aminoisobutyric acid (BAIBA) and biomarkers commonly assessed by physicians to evaluate healthy. Participants will observe a minimum of 48 hours washout between conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Maltodextrin |
|
| 1500 mg L-Valine | Active Comparator | 1500 mg L-Valine |
|
| 250 mg Beta-Aminoisobutryic Acid | Experimental | 250 mg Beta-Aminoisobutryic Acid |
|
| 500 mg Beta-Aminoisobutryic Acid | Experimental | 500 mg Beta-Aminoisobutryic Acid |
|
| 1500 mg Beta-Aminoisobutryic Acid | Experimental | 1500 mg Beta-Aminoisobutryic Acid |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Beta-Aminoisobutyric Acid | Dietary Supplement | All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol. |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma concentrations of BAIBA. | Plasma concentrations of BAIBA. | 4 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Complete Blood Count | Plasma and serum indicators of health | 4 hours |
| Comprehensive Metabolic Panel | Plasma and serum indicators of health |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lindenwood University | Saint Charles | Missouri | 63301 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36184601 | Derived | Krieger JM, Hagele AM, Orr LS, Walden KE, Gross KN, Mumford PW, Kerksick CM. Dose-Response Absorption Kinetics of Oral L-Beta-Aminoisobutyric Acid (L-BAIBA) Supplementation in Healthy Men and Women. J Diet Suppl. 2023;20(6):832-849. doi: 10.1080/19390211.2022.2128141. Epub 2022 Oct 2. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C033435 | 3-aminoisobutyric acid |
Not provided
Not provided
Not provided
Randomized, double-blind, placebo-controlled, crossover design
Not provided
Not provided
Supplements blinded to participant and investigator by third party
|
| 4 hours |
| Adverse Events | Incidence and associations of reported adverse events | 4 hours |